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Abstract
Background: Patient-reported outcomes have been associated with survival in numerous studies across cancer
types, including breast cancer. However, the Brief Pain Inventory-Short Form (BPI-SF) and the Rotterdam Symptom
Checklist (RSCL) have rarely been investigated in this regard in breast cancer.
Methods: Here we describe a post hoc analysis of the prognostic effect of baseline scores of these instruments on
survival in a phase III trial of patients with advanced breast cancer who received gemcitabine plus paclitaxel or
paclitaxel alone after anthracycline-based adjuvant or neoadjuvant therapy. The variables for this analysis were
baseline BPI-SF “worst pain” and BPI-SF “pain interference” scores, and four RSCL subscales (each transformed to
0–100). Univariate and multivariate Cox models were used, the latter in the presence of 11 demographic/clinical
variables. Kaplan-Meier curves and log-rank tests were used to compare survival for patients by BPI-SF or RSCL
scores.
Results: Of 529 randomized patients, 286 provided BPI-SF data and 336 provided RSCL data at baseline. Univariate
analyses identified BPI-SF worst pain and pain interference (both hazard ratios [HR], 1.07 for a 1-point increase;
both p ≤ 0.0061) and three of four RSCL subscales [activity level, physical distress, and health-related quality of life
(HRQOL) (HR, 0.86–0.91 for 10-point increase all p ≤ 0.0104)], to have significant prognostic effect for survival. BPI-SF
worst pain (p = 0.0342) and RSCL activity level (p = 0.0004) were prognostic in the multivariate analysis. Median
survival for patients categorized by BPI-SF worst pain score was 23.8 (n = 91), 17.9 (n = 94) and 14.6 (n = 94) months
for scores 0, 1–4, and 5–10, respectively (log-rank p = 0.0065). Median survival was 23.8 and 14.6 months for patients
(n = 330) with above- and below-median RSCL activity level scores respectively (log-rank p < 0.0001).
Conclusion: Pretreatment BPI-SF worst pain and RSCL activity scores provide distinct prognostic information for
survival in patients receiving paclitaxel or gemcitabine plus paclitaxel for advanced breast cancer even after
controlling for multiple demographic and clinical factors.
Trial registration: Clinicaltrials.gov, NCT00006459.
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Background
Breast cancer is the most common malignancy world-
wide and the largest cause of cancer-related death in
women [1]. With advancements across screening and
treatment modalities over the past 3 decades, evidence
from institutional databases and clinical trials [2, 3] sug-
gests that patients with metastatic breast cancer (MBC)
are surviving longer than the median of 18–24 months
that has been traditionally reported [4]. However, it un-
fortunately still remains an incurable disease in nearly all
instances, and the goal of treatment is to palliate or pre-
vent symptoms, delay disease progression, and prolong
survival [4]. Patients living with advanced disease can
experience diminished health-related quality of life
(HRQOL) due to cancer- and treatment-related symp-
toms, such as pain, fatigue, cognitive dysfunction, sleep
disturbances, arm morbidity, neuropathy, and meno-
pausal symptoms [5, 6].
Self- report from cancer patients provides a unique
perspective that addresses aspects of wellbeing, feelings,
and functioning, which may not be otherwise captured
with standard clinical assessments [7]. Patients who have
reported worsening of symptoms and HRQOL have also
experienced deterioration in their clinical condition [7, 8].
Research has shown that HRQOL-related information can
serve as a useful adjunct to conventional clinical assess-
ments for oncology patients by improving patient-
clinician communication and, in particular, helping clini-
cians understand patient challenges from a psychosocial
perspective [7, 9–16]. Understanding all of these factors is
increasingly important in oncology in order to optimize
the care of patients [17–20].
Patient-reported outcome data obtained from validated
instrumentation have demonstrated consistency and reli-
ability in association with clinical outcomes for cancer
and non-cancer conditions [21, 22]. Given the increasing
potential for such data to be clinically informative
[23, 24], patient-reported outcomes and symptoms
have emerged as important measures of cancer treat-
ment in clinical trials. Stratifying patients in clinical
trials by baseline HRQOL can result in more homo-
geneous treatment groups and allow for better under-
standing of study results [25].
Patient-reported outcomes, assessed via a variety of
different instruments, have shown independent prognos-
tic value for survival in post hoc analyses of clinical trials
[26–29] and in observational studies of MBC patients
undergoing cancer treatment [30, 31]. The prognostic
value of HRQOL and associated domains has also been
demonstrated in an exploratory fashion across other
solid-tumor-specific studies, [7, 32–39] as well as in
systematic reviews and meta-analyses [7, 25]. A recent
analysis of 7417 patients examined the relative value of
different HRQOL domains for multiple cancer types
using the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life
Questionnaire-Core 30 (QLQ-C30). Results demon-
strated that HRQOL parameters of greatest prognostic
value differed by cancer type, and the effect size of
each parameter varied according to tumor site. For
breast cancer as well as other cancer types, at least
one domain provided additional prognostic informa-
tion to that obtained from clinical and sociodemo-
graphic variables [23].
The current report is an exploratory, post hoc analysis
of clinical and HRQOL outcomes from a phase III trial
comparing gemcitabine plus paclitaxel with paclitaxel
alone in patients with advanced breast cancer. As previ-
ously reported [40], patients receiving doublet therapy
experienced significantly improved survival versus pacli-
taxel alone and were also more likely to have improved
HRQOL over time as measured by the Brief Pain
Inventory-Short Form (BPI-SF) and Rotterdam Symptom
Checklist (RSCL). Here we evaluate the prognostic effect
of BPI-SF and RSCL baseline scores on survival. The
BPI-SF is used extensively in clinical practice [41] and it
has been used across many studies in breast cancer to
assess pain. To our knowledge, however, this is the first
exploratory report evaluating the prognostic significance
of baseline pain and the relationship to survival utilizing
this instrument. Other studies in advanced breast cancer
to date have utilized the RSCL [42–44] although none
have reported the prognostic significance of baseline
scores. The current analysis therefore adds to the body
of research by evaluating the prognostic effect of base-
line scores for pain and other HRQOL domains on sur-




This was a post hoc analysis of a phase III, multi-
national, clinical trial evaluating paclitaxel with and
without gemcitabine in women with advanced breast
cancer who relapsed after adjuvant or neoadjuvant
therapy with an anthracycline, or non-anthracycline if
there was a contraindication (Clinicaltrials.gov identifier
NCT00006459). As reported by Albain et al. [40], eli-
gible patients were to have had Karnofsky Performance
Status (KPS) ≥ 70, adequate bone marrow reserve, liver
and renal function, normal calcium levels, and an esti-
mated life expectancy of ≥12 weeks at baseline. Prior
systemic treatment for metastatic disease was not
allowed. Patients were randomly allocated to paclitaxel,
with or without concurrent gemcitabine, and treatment
cycles continued until disease progression, unacceptable
toxicity, or patient withdrawal. There were 529 random-
ized patients from 19 countries. The primary endpoint
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was overall survival, which was defined as the time from
randomization to death from any cause, and surviving pa-
tients were censored at the last visit date. Patients com-
pleted the BPI-SF and the RSCL within 1 week prior to
randomization and at the end of each treatment cycle. Both
the questionnaires were completed by patients for whom
validated translations were available. The RSCL was in-
cluded in this study to better understand the impact of
treatment on patient’s symptoms and the influence of
symptoms on physical and psychological function. The
BPI-SF was included to allow a more focused evaluation of
pain, which is not specifically evaluated by the RSCL. Effi-
cacy, safety, and patient-reported outcomes results have
been previously reported [40, 45, 46]. The study was con-
ducted according to Declaration of Helsinki and good clin-
ical practice guidelines, and was approved by each
participating center’s ethics review board. All patients
signed informed consent forms that described the clinical
and HRQOL components of the study.
Patient-reported outcome instrumentation
The BPI-SF is a valid and reliable instrument [41], originally
developed to assess chronic pain and its impact on HRQOL
[47]. This instrument is widely used in clinical practice set-
tings and research to measure the impact of cancer pain
[41]. Patients rate their pain and its effects as experienced
in the preceding 24 hours. The BPI-SF measures pain in-
tensity (worst, least, average, current), pain relief, and inter-
ference of pain (on 7 HRQOL dimensions of general
activity, mood, walking, normal work, relations with others,
sleep, and enjoyment of life). Scores for the worst pain item
as well as pain interference were used in this analysis.
Worst pain scores range from 0 (no pain) to 10 (worst
pain). Pain interference scores range from 0 (no interfer-
ence) to 10 (complete interference) and were calculated as
the mean of the seven pain interference items.
The RSCL is a validated instrument for measuring
HRQOL and symptoms in cancer patients [48, 49]. The
instrument assesses symptoms and effects of symptoms
on anxiety, depression, functional status, and quality of life
during the week prior to completing the questionnaire. It
has been used previously by patients with advanced breast
cancer [44, 50], as well as in numerous other cancer trials
[51–55]. Patients answer items for different symptoms via
a Likert scale (not at all, a little, quite a bit, very much)
comprising four dimensions: physical distress (23 items),
psychological distress (7 items), activity level (8 items),
and a single item to measure overall HRQOL. For the pur-
poses of this study, the RSCL subscales were each trans-
formed to 0–100, with 100 as the best score.
Statistical analyses
The present post hoc analysis utilized patient-reported
outcome scores measured at baseline only. All patients
with a baseline BPI-SF or RSCL assessment were in-
cluded, and data from the two study treatment arms
were combined for all analyses.
The associations between baseline measures of clinician-
assessed KPS and patient-assessed BPI-SF and RSCL sub-
scale scores were analyzed using one-way analyses of vari-
ance (ANOVA). Univariate Cox proportional hazards
models were used to determine the prognostic effect of
each variable on survival. Multivariate Cox proportional
hazard models were used to determine the prognostic effect
of each RSCL and BPI-SF score in the presence of 11 base-
line demographic and clinical prognostic factors that had
been used in the clinical study for randomization stratifica-
tion or preplanned subgroup analyses. In general, a finding
of an effect in a univariate analysis is sufficient to show that
the subscale provides prognostic information for survival;
the same finding in a multivariate analysis suggests that the
prognostic value is additional to what could be obtained
from demographic and clinical characteristics. For the
current analysis, all were assessed as binary categorical vari-
ables: KPS (<90 vs ≥90), estrogen receptor status (positive
vs negative), progesterone receptor status (positive vs nega-
tive), presence of visceral disease (yes vs no), age (<65 vs
≥65), prior radiotherapy (yes vs no), prior hormonal treat-
ment (yes vs no), menopausal status (pre- or peri-
menopausal vs post-menopausal), basis for pathologic diag-
nosis (histological vs cytological), race (Caucasian vs non-
Caucasian), and pathologic diagnosis (ductal vs non-
ductal). Kaplan-Meier curves and log-rank tests were used
to compare survival among patient groups categorized into
three and two categories for the BPI-SF [56] and the RSCL
respectively. The categories of the BPI-SF were divided into
approximately equal numbers of patients: worst pain scores
(0 = no pain, 1 to 4 =mild pain, 5 to 10 =moderate/severe
pain), pain interference scores (0 to <0.5 = no interference,
≥0.5 to <4.5 =mild interference, ≥4.5 to ≤10 =moderate/se-
vere interference). Dichotomized patient groups (>median,
≤ median) were evaluated for each of the four RSCL sub-
scale scores; a choice of baseline median as the cut point
was made by the study team so as to evaluate similar num-
bers of patients above and below the median. Statistical sig-
nificance was defined as p ≤ 0.05, and no adjustment was
made for multiplicity. All statistical analyses were con-
ducted using SAS® version 9.2 or later version.
Results
Patient population and baseline characteristics
Table 1 shows the baseline demographic and disease
characteristics of patients who contributed data to this
analysis. This analysis included all patients who com-
pleted the BPI-SF (n = 286) and RSCL (n = 336)
questionnaires at baseline. Approximately one-third to one-
half of patients in the original study did not complete these
assessments primarily due to a lack of a validated
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translation of the questionnaire in their language [46]. Pa-
tient demographic and clinical characteristics were compar-
able between those who completed the BPI-SF or the
RSCL, with the majority of patients less than 65 years of
age, post-menopausal, Caucasian, and having metastatic
disease at diagnosis. Additionally, similar proportions of pa-
tients in each group were estrogen or progesterone receptor
positive or negative, had ductal or non-ductal breast carcin-
oma, and received prior radiotherapy or hormonal therapy.
The number of patients eligible to complete the RSCL
based on validated translations was 368. However, 32 pa-
tients did not complete the RSCL at baseline due to failure
by the site to administer (n = 11), patient refusal (n = 11), or
other reasons, the specifics of which were not docu-
mented (n = 10). The number of patients eligible to
complete the BPI based on validated translations was
308. Of these, 22 patients did not complete the BPI
at baseline due to failure by the site to administer (n
= 8), patient refusal (n = 9), or other reasons (n = 5).
Association of the BPI-SF and RSCL Scores with KPS
Given the role of clinician-assessed performance status
as a clinical measure in these patients, we sought to
specifically characterize the association between patient-
assessed BPI-SF and RSCL versus KPS. Both BPI-SF
variables (pain interference and worst pain) were signifi-
cantly associated with KPS (pain interference p ≤ 0.0001;
worst pain p = 0.0030). Patients with better performance
status (higher KPS) had less pain interference and less
intensity of worst pain (Table 2). There was a positive
Table 1 Baseline Demographic and Disease Characteristics for





Number of patients with baseline
assessment
286 336
Age, median (range) 55 (27–83) 54 (27–83)
Age≥ 65 years (n, %) 56 (19.6) 59 (17.6)
Ethnicity, n (%)
Caucasian 202 (70.6) 220 (65.5)
Asian 15 (5.2) 16 (4.8)
Hispanic 55 (19.2) 86 (25.6)
Other 14 (4.9) 14 (4.2)
Stage at entry (n, %)
Unresectable 14 (4.9) 15 (4.5)
Metastatic 272 (95.1) 321 (95.5)
Karnofsky Performance Status (n, %)
< 90 75 (26.2) 86 (25.6)
90 or 100 210 (73.4) 249 (74.1)
Unknown 1 (0.3) 1 (0.3)
Tumor metastatic site (n, %)
Visceral 213 (74.5) 251 (74.7)
Non-visceral only 73 (25.5) 85 (25.3)
Menopausal status
Peri-menopausal 10 (3.6) 12 (3.6)
Post-menopausal 237 (84.3) 277 (83.7)
Pre-menopausal 34 (12.1) 42 (12.7)
Unknown 5 (1.7) 5 (1.5)
Estrogen receptor status (n, %)
Positive 117 (40.9) 133 (39.6)
Negative 120 (42.0) 141 (42.0)
Unknown 49 (17.1) 62 (18.5)
Progesterone receptor status
Positive 101 (35.3) 113 (33.6)
Negative 123 (43.0) 146 (43.5)
Unknown 62 (21.7) 77 (22.9)
Pathologic diagnosis
Ductal breast carcinoma 228 (79.7) 276 (82.1)
Non-ductal breast carcinoma 58 (20.3) 60 (17.9)
Basis for pathologic diagnosis
Histopathological 257 (89.9) 303 (90.2)
Cytological 29 (10.1) 33 (9.8)
Prior radiotherapy
Yes 196 (68.5) 238 (70.8)
No 90 (31.5) 98 (29.2)
Table 1 Baseline Demographic and Disease Characteristics for
Patients Who Provided BPI-SF or RSCL at Baseline (Continued)
Prior hormone therapy
Yes 151 (52.8) 164 (48.8)
No 135 (47.2) 172 (51.2)
BPI-SF Brief Pain Inventory-Short Form, RSCL Rotterdam Symptom Checklist
Table 2 Mean BPI-SFa by KPS
KPS BPI-SF – Pain Interference BPI-SF – Worst Pain
n Mean (SD) n Mean (SD)
Overallb 281 2.2 (2.63) 278 3.2 (3.03)
≤70 23 4.6 (3.67) 23 4.6 (3.60)
80 51 2.8 (2.75) 49 4.1 (2.82)
90 100 1.9 (2.38) 100 3.3 (2.88)
100 107 1.6 (2.19) 106 2.5 (2.94)
p < 0.0001c p = 0.0030c
BPI-SF Brief Pain Inventory-Short Form, KPS Karnofsky Performance Status, SD
standard deviation
aBPI-SF item scores range from 0 (no pain or interference with daily living)
to 10
bOverall patient numbers < 286 because not all answered every BPI-SF item
cP-values derived from one-way analysis of variance
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association between mean RSCL subscale scores and
KPS for activity level, physical distress, and overall
HRQOL, indicating that patients with better perform-
ance status had greater levels of activity and HRQOL as
well as lower levels of physical distress (all p < 0.0001,
Table 3). While there was a positive trend in RSCL
scores with increasing KPS, there was no significant as-
sociation between KPS and the psychological distress
subscale (p = 0.1630).
Prognostic Effect of BPI-SF and RSCL on Survival
In the univariate analyses, patients with higher BPI-SF
scores (indicating worse pain or pain interference) had
lower survival rates. In the case of the RSCL, patients
with higher scores (indicating lower symptom burden)
had better survival. Significant prognostic effects on
survival were observed for baseline scores of both
BPI-SF worst pain and pain interference (both
hazard ratios [HRs], 1.07 for 1-point increase; both
p ≤ 0.0061) and three of the four RSCL subscales (ac-
tivity level, physical distress, and overall HRQOL)
(HR, 0.86–0.91 for 10-point increase; all p ≤ 0.0104;
Table 4). Psychological distress had no significant
prognostic effect on survival.
In the multivariate analyses, the BPI-SF worst pain item
and the RSCL activity level remained significant prognos-
tic factors (p = 0.0342, p = 0.0004, respectively; Table 4) in
the presence of the 11 baseline demographic or clinical
variables. The pain interference subscale, physical dis-
tress, and overall HRQOL scores were no longer signifi-
cant. Consistent with the univariate analysis,
psychological distress was not prognostic for survival.
Survival Time by BPI-Worst Pain, Pain Interference, and
RSCL Categories
The median survival time for patients with a BPI-SF
worst pain score of 0 (no pain) was 23.8 months (n =
91), versus 17.9 months (n = 94) for scores 1–4, and
Table 3 Mean RSCLa Subscale Scores by KPS
KPS RSCL – Activity RSCL – Physical RSCL – Psych RSCL – HRQOL
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Overallb 329 83.3 (22.65) 333 83.5 (12.37) 332 64.4 (23.76) 323 66.0 (24.14)
≤70 25 51.2 (27.11) 26 74.4 (14.21) 26 56.5 (26.78) 26 38.5 (28.19)
80 58 71.7 (26.25) 59 78.5 (12.27) 58 60.3 (23.31) 58 58.6 (22.13)
90 110 85.2 (18.62) 111 84.9 (11.75) 111 65.1 (24.19) 109 67.1 (22.39)
100 136 92.7 (14.32) 137 86.2 (11.17) 137 67.1 (22.67) 130 74.0 (20.54)
p = 0.0001c p < 0.0001c p = 0.1630c p < 0.0001c
Activity: Activity level; Physical: Physical distress; Psych: Psychological distress
HRQOL health-related quality of life; KPS Karnofsky Performance Status; RSCL Rotterdam Symptom Checklist; SD standard deviation
a RSCL scores transformed to a range from 0 to 100, with 100 as best score
b Overall patient numbers < 336 because not all answered every RSCL item
cp-values derived from one-way analysis of variance
Table 4 Prognostic Effect of BPI-SF and RSCL on Survival
HRQOL subscale variables a nb HR 95 % CI p-value HR 95 % CI p-value
Univariate Multivariatec
BPI-SF – Pain Interference 282 1.07 1.02–1.12 0.0061 1.02 0.97–1.08 0.3931
BPI-SF – Worst Pain 279 1.07 1.03–1.12 0.0013 1.05 1.00–1.10 0.0342
RSCL – Activity Level 330 0.86 0.82–0.91 <0.0001 0.89 0.83–0.95 0.0004
RSCL – Physical Distress 333 0.88 0.81–0.97 0.0104 0.92 0.83–1.02 0.1053
RSCL – Psychological Distress 332 0.96 0.91–1.01 0.1025 0.98 0.92–1.03 0.3800
RSCL – HRQOL 324 0.91 0.87–0.96 0.0002 0.95 0.90–1.01 0.0810
BPI-SF Brief Pain Inventory-Short Form; CI confidence interval; HR hazard ratio; HRQOL health-related quality of life; KPS Karnofsky Performance Status; n number of
patients with nonmissing values on a variable among randomized patients; RSCL Rotterdam Symptom Checklist
aHRs for every 1-point increase in the BPI-SF and every 10-point increase in the RSCL subscales
bIncludes 1 patient with missing KPS score and not included in Tables 2 and 3. This patient’s scores were as follows: BPI Pain Interference, 0; BPI Worst Pain, 0;
RSCL Activity, 100; RSCL Physical, missing; RSCL Psychological, missing; RSCL HRQOL, 83.33
cMultivariate Cox proportional hazards models were used to determine each HR in the presence of 11 demographic/clinical variables: age, race, KPS, estrogen
receptor status, progesterone receptor status, presence of visceral disease, prior radiotherapy, prior hormonal treatment, menopausal status, basis for pathological
diagnosis, and pathological diagnosis
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14.6 months (n = 94) for scores 5–10 (log-rank p =
0.0065, Fig. 1a). Median survival time for patients with
BPI-SF pain interference scores was 21.2 months (n =
113) (no pain; scores 0 to <0.5) versus 17.6 months (n =
111) (scores ≥0.5 to <4.5) and 14.8 months (n = 58)
(scores ≥4.5 to ≤10; log-rank p = 0.0107; Fig. 1b). The
median survival time was 23.8 months for patients with
median (95.2) or greater activity level scores versus
14.6 months for patients with scores below median (log-
rank p < 0.0001, Fig. 2). Similarly, for the activity, phys-
ical, psychological, and HRQOL subscales, patients with
median or greater scores had significantly better survival
(log-rank p < 0.05, Fig. 2).
Discussion
We have shown in this post hoc analysis that baseline
patient-reported outcomes and symptoms, as measured
by the BPI-SF and RSCL, were prognostic for survival in
patients with locally recurrent or metastatic breast car-
cinoma who received gemcitabine with or without pacli-
taxel. The use of two different, validated instruments
was informative when exploring this prognostic effect in
that they measure distinct aspects of HRQOL in cancer
patients [57], and the present study allowed for a model-
dependent sensitivity analysis.
In this study, the worst pain and pain interference
measures of the BPI-SF as well as activity level, physical
distress, and HRQOL scores of the RSCL were all prog-
nostic for survival in the univariate analysis. The BPI-SF
worst pain and RSCL activity subscales retained a statis-
tically significant effect in the multivariate analysis,
which incorporated clinical, and sociodemographic vari-
ables commonly used as prognostic indicators in advanced
breast cancer (Table 4). Clinical factors previously reported
as prognostic via multivariate analysis for this study cohort
included time from diagnosis to randomization, number of
tumor sites, estrogen receptor status, and KPS [40].
The RSCL activity subscale had the greatest effect on
survival, as reflected by the hazard ratio in the univariate
analysis (Table 4). In addition, it was the only subscale
to retain a statistically significant effect in the multivari-
ate analysis that considered the other RSCL subscales as
well as baseline clinical or demographic characteristics.
The RSCL psychological distress subscale had no rela-
tionship with survival based on 10-point increments in a
Cox proportional hazards model (Table 4). However, the
dichotomous comparison (above and below median
scores) did reveal a significant difference in survival
curves (log-rank p = 0.0109; Fig. 2). It is important to
note that systematic literature reviews have found only
minimal evidence for prognostic effects of psychosocial
HRQOL domains on cancer survival [7, 58].
The most commonly utilized instruments in MBC
trials include the Functional Assessment of Cancer
Therapy-Breast (FACT-B) and the EORTC QLQ-C30
with or without the EORTC breast cancer-specific mod-
ule, QLQ-BR23 [59]; positive prognostic results have
been demonstrated in previously reported analyses of
advanced breast cancer that used baseline EORTC QLC-
C30 assessments [27–29].
The current exploratory analysis of a clinical study
population further adds to the body of evidence that
patient-reported outcomes and symptoms can be prog-
nostic indicators in patients with advanced breast cancer
Fig. 1 Kaplan-Meier Survival Curves by BPI-Worst Pain Categories. a
Worst Pain b Pain Interference
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and as such, a useful adjunct for informing the routine
care of patients. It is important to note that because
patient-reported responses can be subject to social and
environmental factors, this information is best used as
an added tool to all other demographic and clinical con-
siderations that are part of patient care [9]. The reasons
for the relationship between patient-reported outcomes
and symptoms, and survival have not been completely
elucidated. However, it is thought that patient-reported
outcomes may be sensitive to disease progression or
markers of patient behaviors or other characteristics,
such as treatment adherence or healthy lifestyles [7].
In addition, the inclusion of multiple items in patient
survey instruments may enhance their diagnostic sen-
sitivity whether in clinical management or in oncol-
ogy drug trials [7].
It is important to reiterate that the current study
was a post hoc analysis of HRQOL data originally
Fig. 2 Kaplan-Meier Survival Curves by Rotterdam Symptom Checklist (RSCL) Categories. a. Activity Level. b. Physical Distress. c. Psychological Distress.
d. Overall Health-Related Quality of Life (HRQOL). * Multivariate Cox proportional hazards models were used to determine each hazard ratio (HR) in
the presence of 11 demographic/clinical variables: age, race, KPS, estrogen receptor status, progesterone receptor status, presence of visceral
disease, prior radiotherapy, prior hormonal treatment, menopausal status, basis for pathological diagnosis, and pathological diagnosis.
Reference is the < median group; Q50 is the median of each RSCL subscale
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recorded as secondary outcomes in a prospective
clinical trial [46]. Although not all randomized pa-
tients were included in the analyses due to limited
availability of translations of the BPI-SF and RSCL, a
high percentage of the patients with translations
available to them completed the questionnaires; fur-
thermore because only baseline questionnaire re-
sponses were used, there was less potential for
nonrandom missing data. Prognostic factors in the
current study were not defined prior to study enroll-
ment, and no adjustments were made for multipli-
city. Therefore, it would be worthwhile to evaluate
the hypothesis prospectively in order to further sup-
port the utility of patient-survey instruments for the
added benefit of assessing patient prognosis both in
clinical trials as well as in routine clinical practice. If
confirmed, these data could be used to potentially
identify appropriate cut points for the purposes of
prognostic evaluation and study stratification. It is
important to reiterate that these findings are specific
to first-line advanced disease and cannot be general-
ized to other lines of therapy. Furthermore, results
discordant with those of other studies may have
been due to differences in statistical techniques or
instrumentation.
Conclusion
In conclusion, this post hoc analysis of patients with ad-
vanced breast cancer showed that pretreatment BPI-SF
worst pain and RSCL activity scores provide additional
prognostic information for survival beyond that available
from standard demographic and clinical characteristics.
Our findings further support the concept that patient-
reported outcomes can be useful additional prognostic
factors in advanced breast cancer and help guide effect-
ive clinical decision making by revealing manifestations
of malignant disease not systematically evaluated by for-
mal clinical measures.
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